Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Non-Current Deffered Revenue (2016 - 2018)

Viking Therapeutics' Non-Current Deffered Revenue history spans 4 years, with the latest figure at $12000.0 for Q4 2018.

  • For Q4 2018, Non-Current Deffered Revenue changed N/A year-over-year to $12000.0; the TTM value through Dec 2018 reached $12000.0, changed N/A, while the annual FY2018 figure was $12000.0, N/A changed from the prior year.
  • Non-Current Deffered Revenue for Q4 2018 was $12000.0 at Viking Therapeutics, up from $6054.0 in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $31239.0 in Q4 2015 and bottomed at $6054.0 in Q2 2017.
  • The 4-year median for Non-Current Deffered Revenue is $19149.0 (2015), against an average of $18706.3.
  • The largest annual shift saw Non-Current Deffered Revenue rose 6.93% in 2016 before it crashed 75.44% in 2017.
  • A 4-year view of Non-Current Deffered Revenue shows it stood at $31239.0 in 2015, then crashed by 47.8% to $16307.0 in 2016, then plummeted by 62.87% to $6054.0 in 2017, then skyrocketed by 98.22% to $12000.0 in 2018.
  • Per Business Quant, the three most recent readings for VKTX's Non-Current Deffered Revenue are $12000.0 (Q4 2018), $6054.0 (Q2 2017), and $10862.0 (Q1 2017).